Seth J Baum
Overview
Explore the profile of Seth J Baum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
2034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosenson R, Lopez J, Gaudet D, Baum S, Stout E, Lepor N, et al.
JAMA Cardiol
. 2025 Feb;
PMID: 39937508
Importance: Lipoprotein(a) (Lp[a]) is thought to be the major carrier of oxidized phospholipids (OxPL). OxPL are believed to be a potent driver of inflammation and atherosclerosis. Olpasiran, a small interfering...
2.
Shapiro M, Haddad T, Weintraub H, Baum S, Abdul-Nour K, Sarwat S, et al.
J Clin Lipidol
. 2025 Feb;
19(1):28-38.
PMID: 39909772
Background: Elevated lipoprotein(a) (Lp[a]) is the most common inherited dyslipidemia that is independently and causally associated with increased atherosclerotic cardiovascular disease (ASCVD) risk. However, data from diverse populations with ASCVD...
3.
Kaur G, Rosenson R, Gencer B, Lopez J, Lepor N, Baum S, et al.
Eur Heart J
. 2024 Nov;
PMID: 39565305
No abstract available.
4.
Zile M, Borlaug B, Kramer C, Baum S, Litwin S, Menon V, et al.
Circulation
. 2024 Nov;
151(10):656-668.
PMID: 39556714
Background: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic...
5.
Packer M, Zile M, Kramer C, Baum S, Litwin S, Menon V, et al.
N Engl J Med
. 2024 Nov;
392(5):427-437.
PMID: 39555826
Background: Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data...
6.
Borlaug B, Zile M, Kramer C, Baum S, Hurt K, Litwin S, et al.
Nat Med
. 2024 Nov;
31(2):544-551.
PMID: 39551891
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular-kidney end-organ damage. In the SUMMIT trial, patients with HFpEF and...
7.
ODonoghue M, Rosenson R, Lopez J, Lepor N, Baum S, Stout E, et al.
J Am Coll Cardiol
. 2024 Aug;
84(9):790-797.
PMID: 39168564
Background: Olpasiran, a small interfering RNA (siRNA), blocks lipoprotein(a) (Lp(a)) production by preventing translation of apolipoprotein(a) mRNA. In phase 2, higher doses of olpasiran every 12 weeks (Q12W) reduced circulating...
8.
MacDougall D, Baum S, Ahmed C, McGowan M, Wilemon K
Circ Cardiovasc Qual Outcomes
. 2024 Feb;
17(2):e009988.
PMID: 38362767
No abstract available.
9.
Harrison S, Bedossa P, Guy C, Schattenberg J, Loomba R, Taub R, et al.
N Engl J Med
. 2024 Feb;
390(6):497-509.
PMID: 38324483
Background: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH...
10.